As 2024 comes to an end, we reflect on a year of progress and breakthroughs in non-small cell lung cancer care. From advancements in screening technology to treatment options, this year has been filled with progress thanks to the collective hard work of patients, advocates, researchers, healthcare teams, and communities.

Here’s a look at a few of the monumental developments in lung cancer research and treatment this year.

January 2024

• FDA Approves New Drug for Non-Small Cell Lung Cancer With ROS1 Fusions
• ClearNote Health Announces New Proprietary Approach for Predicting Immunotherapy Treatment Response in Non-Small Cell Lung Cancer Using Only Blood
• FDA Grants FTD to Avutometinib/Sotorasib in KRAS G12C–Mutated NSCLC

February 2024

• Quality Improvement Project Bridges ‘Significant Gap’ in Biomarker Testing for Lung Cancer
• Combination Therapy Offers Breakthrough in NSCLC Treatment
• FDA Approves Tepotinib for Metastatic NSCLC Harboring MET Exon 14 Skipping Alterations
• The American Cancer Society (ACS) Updates its Recurring Screening Guidelines for NSCLC

March 2024

• FDA Approves Rybrevant-Chemo Combination for EGFR-Positive Lung Cancer
• SBRT Shines in Early-Stage NSCLC and Demonstrates Efficacy With Immunotherapy

April 2024

• Neoadjuvant Chemoimmunotherapy Shows Superiority in Non–Small Cell Lung Cancer Treatment
• The FDA Expanded the Approval of Roche’s Alecensa to Include Adjuvant Treatment of Non-small Cell Lung Cancer

May 2024

• Alectinib Approved as an Adjuvant Treatment for Lung Cancer
• Cancer Vaccines are Having a Renaissance
• Pfizer’s Lorbrena Extends Life for Patients with Rare Lung Cancer

June 2024

• AstraZeneca and Daiichi Sankyo’s ADC Improves Survival in NSCLC Trial
• Tagrisso Delivers 84% Improvement on the Time Patients Can Live Without Progression
• Injectable Treatment Offers Better Outcomes than Intravenous Alternative
• FDA grants Priority Review to TAGRISSO for Patients with Unresectable, Stage III EGFR-mutated Lung Cancer
• Amivantamab/Chemotherapy Prolongs Progression-Free Survival in NSCLC

July 2024

• Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases

August 2024

• FDA Approves lazertinib with amivantamab-vmjw for Non-small Lung Cancer
• Proposed Lung Cancer Screening Guideline Could Eliminate Racial Disparities, Allow for Early Detection
• BioNTech Initiates Global Trials of mRNA-based Lung Cancer Vaccine

September 2024

• FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection
• FDA approves amivantamab-vmjw with carboplatin & pemetrexed for NSCLC.
• FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy

October 2024

• Nivolumab NSCLC Approval Expanded to Perioperative Setting
• Quality Improvements in Lung Cancer Surgery and Tumor Pathology May Extend Survival Postsurgery
• Neoadjuvant/Adjuvant Pembrolizumab Combo Improves OS in NSCLC
• Drug Improves Effectiveness of Radiation for Lung Cancer that Has Spread to the Brain
• Wearable Tumor-Zapping Medical Device Wins FDA Approval for Lung Cancer

November 2024

• Robotics and Beyond: Advances in Lung Cancer Surgery

December 2024

• Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
• ‘State of Lung Cancer’ Reports Lung Cancer Survival Rate has Increased by 26% Nationally to 28.4%

As we look ahead to 2025, Outcomes4Me remains committed to empowering lung cancer patients with the knowledge and resources they need to navigate their care. 

If you would like to connect with an Outcomes4Me oncology nurse practitioner at no charge through the Outcomes4Me app, using the “Ask Outcomes4Me” button.